COVID-19 related clinical trial disruption concerns lead across geographies: Survey

25 February 2021 (Last Updated February 25th, 2021 15:05)

Clinical trial disruption concerns related to the COVID-19 pandemic topped across various geographies as the outbreak delayed or led to the suspension of enrolment for such trial programmes across the globe.

Clinical trial disruption concerns related to the COVID-19 pandemic topped across various geographies as the outbreak delayed or led to the suspension of enrolment for such trial programmes across the globe.

GlobalData conducted a poll to identify primary business concerns related to coronavirus outbreak in North America, Europe, Asia Pacific and Rest of the World (RoW).

Primary business concern related to COVID-19 by geography

Primary Business Concerns Related to the Covid-19 Outbreak by Geography 

Clinical trial disruption was the primary business concern according to a majority 28% of the respondents in Europe. The same opinion was shared by 26% of the respondents in North America, 26% in RoW and 20% in Asia Pacific.

Around 21% of the companies in North America noted that the safety of the patients recruited in the trials is their biggest concern. The figure stood at 20% in Europe, 16% in Asia Pacific and 14% in RoW.

Employee safety emerged as a major concern in Asia Pacific and RoW, according to 20% of the respondents each who expressed their apprehension about the well-being of their staff amid the pandemic. In Europe and North America, the figure stood at 16%.

The survey also found that concerns related to contract research organisations (CRO) disruptions are higher in Europe (14%) and North America (12%) than in Asia Pacific (7%) and RoW (6%).

Furthermore, the percentage of respondents who felt that the impact on supply chains is of the highest concern stood at 17% in RoW, 16% in Asia Pacific, 11% in North America and 8% in Europe.

Approximately 14% of the respondents in Asia Pacific opined that business development is the main concern, followed by 10% in North America, 8% in Europe and 6% in RoW.

Capital raising concerns were highest among respondents from the RoW (11%), followed by Asia Pacific (7%), North America (4%) and Europe (3%).

The analysis is based on responses received for Coronavirus Survey – COVID-19 and Decentralised Clinical Trials conducted by GlobalData between 04 June and 22 June 2020.